top of page

Thu, Dec 05

|

The Capital Grille

THE ROLE OF JAKAFI IN STEROID-REFRACTORY ACUTE GVHD

Registration is Closed
See other events
THE ROLE OF JAKAFI IN STEROID-REFRACTORY ACUTE GVHD
THE ROLE OF JAKAFI IN STEROID-REFRACTORY ACUTE GVHD

Time & Location

Dec 05, 2019, 5:00 PM – 8:00 PM

The Capital Grille, Hynes Convention Center, 900 Boylston St, Boston, MA 02115, USA

Guests

About The Event

You are cordially invited to attend a program:

THE ROLE OF JAKAFI IN STEROID-REFRACTORY ACUTE GVHD

Presented by: 

Paul Larson, MSN, NP

Program Summary: 

This promotional presentation will review diagnosis, staging, and grading of acute graft-versus-host disease (GVHD), identification of patients with steroid-refractory acute GVHD, and use of Jakafi® (ruxolitinib), a targeted JAK1/JAK2 inhibitor, for these patients. Data from the REACH1 study will be reviewed, along with important safety information for Jakafi.

Program Objectives:

• Review the diagnosis, staging, and grading of acute GVHD • Describe the definitions for steroid-refractory acute GVHD • Describe the proposed mechanism of action of Jakafi in steroid-refractory acute GVHD • Review the Jakafi indication in steroid-refractory acute GVHD • Review the REACH1 study results, including Day 28 overall response rate (primary endpoint) • Describe the safety profile of Jakafi in REACH1 and Important Safety Information for Jakafi • Review Jakafi dosing for adult and pediatric patients 12 years and older with steroid-refractory acute GVHD

RSVP by 12/3/19

Link to Register and learn more about the event: https://events.americanmedicalcomm.com/jakafi/

Share This Event

bottom of page